Xbrane Biopharma AB (7XB0) Financial Statements
Xbrane Biopharma AB Financial Overview
Xbrane Biopharma AB's market cap is currently $26.48M. The company's EPS TTM is $-2.40; its P/E ratio is -5.90; Xbrane Biopharma AB is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 152.35M | $ 198.70M | $ 238.73M | $ 57.62M | $ 11.53M |
| Gross Profit | $ 74.94M | $ 180.47M | $ 35.39M | $ 41.04M | $ -684.00K |
| Operating Income | $ -72.14M | $ -217.92M | $ -310.43M | $ -166.22M | $ -180.40M |
| EBITDA | $ -16.50M | $ -181.97M | $ -282.03M | $ -149.34M | $ -168.37M |
| Net Income | $ 127.24M | $ -266.22M | $ -388.17M | $ -172.23M | $ -191.01M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 86.59M | $ 124.33M | $ 65.40M | $ 193.99M | $ 295.18M |
| Total Assets | $ 671.62M | $ 842.43M | $ 653.51M | $ 690.51M | $ 688.43M |
| Total Debt | $ 58.31M | $ 191.72M | $ 231.48M | $ 38.22M | $ 44.38M |
| Net Debt | $ -28.28M | $ 67.39M | $ 166.08M | $ -155.77M | $ -250.80M |
| Total Liabilities | $ 110.97M | $ 633.89M | $ 482.17M | $ 265.63M | $ 256.69M |
| Stockholders' Equity | $ 560.65M | $ 208.54M | $ 171.34M | $ 424.89M | $ 431.74M |
| Cash Flow | |||||
| Free Cash Flow | $ -390.33M | $ -185.97M | $ -423.45M | $ -254.04M | $ -296.96M |
| Operating Cash Flow | $ -250.69M | $ -133.73M | $ -406.68M | $ -193.92M | $ -219.61M |
| Investing Cash Flow | $ -37.14M | $ -52.25M | $ -16.77M | $ -60.13M | $ -77.35M |
| Financing Cash Flow | $ 255.60M | $ 243.62M | $ 298.70M | $ 148.86M | $ 349.37M |
Currency in SEK